Catalyst

Slingshot members are tracking this event:

Mallinckrodt to complete Phase 4 study of Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients in Q1 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MNK

100%

Additional Information

Additional Relevant Details The primary objective of this study is to assess the proportion of treatment-resistant subjects (defined as subjects who either have had no response or have suffered a relapse after achieving a partial response to their most recent standard treatment regimen) who have a complete or partial remission of proteinuria in nephrotic syndrome due to idiopathic membranous nephropathy after 24 weeks of treatment.
https://clinicaltria...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 4, Acthar, Repository Corticotropin Injection, Proteinuria, Nephropathy, Placebo-controlled, Double Blind